Lorlatinib is a prescription drug that is used in the treatment of adults with non-small cell lung cancer (NSCLC) that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene and that has spread to other parts of the body.
Dosage: The recommended dose is lorlatinib 100mg orally once daily, with or without food, until the unacceptable toxicity is noticed or disease is progressive. Swallow tablets whole. Do not chew, crush or split tablets. Do not ingest if lorlatinib tablets are broken, cracked, or otherwise not intact. Take lorlatinib at the same time each day. If a lorlatinib dose is missed, then take the missed dose unless the next dose is due within four hours. Do not take two doses at the same time to make up for a missed dose. Do not take an additional dose of lorlatinib if vomiting occurs after administering it but continue with the next scheduled dose.
Side Effects: The most commonly reported lorlatinib side effects may include:
- Weight gain
- Mood effects
- Cognitive effects
- Peripheral neuropathy
Warnings and Precautions:
- A healthcare professional will perform a test to make sure that lorbrena uses are appropriate.
- Monitor patients for triglycerides and serum cholesterol prior to initiating lorlatinib 25mg, 1 and 2 months after initiating it, and periodically thereafter.
- Monitor patients for ECG prior to start taking lorbrena dosage and periodically thereafter.
- Due to the potential for severe side effects in breastfed infants, instruct women not to breastfeed during lorlatinib therapy and for 7 days after the last dose.
- The lorlatinib tablet can cause embryo-fetal harm when administered to a pregnant woman.
- Lorlatinib may be responsible for causing decreased fertility in males. In males, this could affect their ability to father a child.